Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Moderna Inc. gained 0.6% in trading on Monday after the company said it hired Kate Cronin, former global CEO of Ogilvy Health, as its first chief brand officer. Moderna has one authorized product in the U.S., its COVID-19 vaccine.

Moderna hires chief brand officer

Pfizer

Scientists found that, even four months after the first dose, the body continues to train new immune cells to protect against Covid-19, which suggests robust protection.

Pfizer And Moderna Vaccines May Offer Years-Long Protection Against Covid-19, Scientists Say

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kate Cronin to join Moderna as Chief Brand Officer on July 12.

Kate Cronin to Join Moderna as Chief Brand Officer on July 12

The FDA mentions cases of heart inflammation in young people.

Could a Vaccine Warning Label Hurt Moderna and Pfizer?

For each Covid-19 vaccine, the fact sheets were revised to include a warning about myocarditis and pericarditis after the second dose

FDA adds warning about risk of rare heart inflammation to Pfizer, Moderna Covid vaccines

It's already a stunning success, and it's just getting started.

This Provocative Biotech Stock Is a Better Bet Than Ethereum or Dogecoin

BioNTech SE

Novavax

The biotech stocks jumped for different reasons.

Why COVID Vaccine Stocks Moderna, Novavax, and BioNTech Soared This Week

Investors are breathing easier after the FDA's response to a potential link between Moderna's vaccine and heart inflammation issues.

Why Moderna Stock Is Climbing Higher Today

Trade Desk

Upstart Holdings

Artificial intelligence and machine learning are competitive advantages they've had from the start.

3 Revolutionary Stocks That Can Make You Rich

Data was presented to a CDC advisory panel suggesting a link between mRNA vaccines and heart inflammation issues in young men.

Why Moderna and BioNTech Stocks Slipped Today

A CDC panel caused shares of Moderna to slide.

Moderna and Other Vaccine Makers Are Dropping. Here's Why.

Shares of COVID-19 vaccine companies Moderna Inc (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) are moving sharply lower Wednesday. What Happened: Administering of mRNA vaccines, the class of vaccines developed by Moderna and Pfizer-BioNTech, resulted in higher observed vs.

Moderna, Pfizer Stocks Fall After CDC Panel Flags Heart Inflammation Risk In Young Adults Receiving COVID-19 Vaccine

DocuSign

Match Group

Peloton

Atlassian

After the wild swings last month, the tech-heavy Nasdaq Composite Index has been gaining momentum lately and reached a new peak driven by tech rally.

5 Hot Stocks That Pushed Nasdaq ETF to New Highs

AstraZeneca

CureVac B.V

Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.

How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

Albertsons Companies

Nextdoor teamed up with Moderna and Albertsons on a Covid-19 vaccine map. The map will allow users to locate vaccination sites and schedule an appointment.

Social media app Nextdoor teams with Moderna, Albertsons to boost vaccination rates in communities

The company announced another big European supply deal.

Why Moderna Stock Jumped 6% Today

MRNA has a market capitalization of over $80 billion. MRNA bulls may believe the company could dominate the market for booster shots. The need for booster shots still remains unproven. MRNA may have jumped the shark, in my opinion.

Moderna Jumps The Shark

The European Union has decided to take up an option under a supply contract with Moderna Inc (NASDAQ: MRNA) that allows the bloc to order 150 million additional COVID-19 vaccines. This purchase brings the European Commission's confirmed order commitment to 460 million doses.

Europe Purchases Additional 150M Doses Of Moderna COVID-19 Vaccine

Bio-Path Holdings

vTv Therapeutics

Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna announced that the European Commission has purchased an additional 150 million doses of COVID-19 vaccine.

Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today

The company is using technology to distance itself from the pack.

Is This the Secret Ingredient That Could Make Moderna Shareholders Rich?

Shares of Moderna Inc. gained 2.1% in premarket trading on Tuesday after the company said the European Commission has purchased an additional 150 million doses of its COVID-19 vaccine. These shots are set to be delivered in 2022.

Europe buys another 150 million doses of Moderna's COVID-19 vaccine, including option to buy boosters

CAMBRIDGE, Mass.--(BUSINESS WIRE)--European Commission purchases additional 150 million doses of Moderna's COVID-19 vaccine for delivery in 2022.

European Commission Purchases Additional 150 Million Doses of Moderna's COVID-19 Vaccine for Delivery in 2022

New research published in JAMA found there was no difference in sperm parameters in 45 men who received mRNA vaccines against COVID-19. The two authorized mRNA vaccines, which were developed by Pfizer Inc. and Moderna Inc. , are the most commonly utilized COVID-19 vaccines in the U.S. Researchers at the University of Miami Miller School of Medicine say they initiated the study after hearing concerns from some people that the vaccines could impact fertility.

New research says Pfizer and Moderna's mRNA vaccines don't affect sperm parameters

Investors seemed to yawn over a really big new deal for the vaccine maker.

Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared

Moderna Inc (NASDAQ: MRNA) will be adding two new production lines at the rebuilt former Polaroid plant where it manufactures its COVID-19 vaccine to prepare for making booster shots. The company is getting one new line up and running by fall and the other by early 2022.

News for Moderna Stock (MRNA)